Morris Ronnie
Known title: CEOCIK: 0001504443
Morris Ronnie's purchase track record
Morris Ronnie has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/17/2023 | CSBR | $50K | +70.3% | +31.3% | +13.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CSBR | ▲ Buy | Open Market | 12,382 | $50K | 3/17/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Champions Oncology Highlighted in Global PDX Models Shift
Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.
Champions Oncology Highlighted in Global PDX Models Shift. Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.